US Stock MarketDetailed Quotes
RNAZ Transcode Therapeutics
- 0.342
- -0.043-11.05%
Trading Nov 25 13:29 ET
5.90MMarket Cap-395P/E (TTM)
0.381High0.330Low780.03KVolume0.377Open0.385Pre Close268.01KTurnover4.52%Turnover RatioLossP/E (Static)17.27MShares9.60052wk High3.56P/B5.90MFloat Cap0.21652wk Low--Dividend TTM17.26MShs Float5600.000Historical High--Div YieldTTM13.24%Amplitude0.216Historical Low0.343Avg Price1Lot Size
Transcode Therapeutics Stock Forum
Sign in to post a comment
$Transcode Therapeutics (RNAZ.US)$ well the RS makes sense with the chart but look for a run tonight or soon but get out and wait to get back in after RS when float is tiny af.. will be 2-3 plays before a good update really spikes it to get wrecked back to under 1.00 again after that RS
1
$Transcode Therapeutics (RNAZ.US)$
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-33 reverse stock split. The reverse stock split was approved by TransCode's stockholders on November 22, 2024, and is inte...
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-33 reverse stock split. The reverse stock split was approved by TransCode's stockholders on November 22, 2024, and is inte...
1
$Transcode Therapeutics (RNAZ.US)$ TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
Dow Jones· 1 min ago
Dow Jones· 1 min ago
1
1
$Transcode Therapeutics (RNAZ.US)$ Reuters· just
Transcode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 Ttx-Mc138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
Transcode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 Ttx-Mc138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
Four companies today that have the potential to explode. GNPX,The first has already exploded, and has warnings from several analysts that it's going to keep going. Next you have SNAP. They have their earnings Today. Named on Zacks as a potential win, and with a History to Blow up. Worth the shot. Next these two companies are the new maxn and muln. They are BNAT && RNAZ. Both Green after a major mountain of interest collapsed, just to tise back up today 🤫
6
3
$Transcode Therapeutics (RNAZ.US)$
BOSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has dosed all patients in the first cohort of its Phase 1a dose-escalation clinical trial. The therapeutic candidate being e...
BOSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has dosed all patients in the first cohort of its Phase 1a dose-escalation clinical trial. The therapeutic candidate being e...
2
1
$Transcode Therapeutics (RNAZ.US)$
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
TransCode Therapeutics (NASDAQ: RNAZ) has completed initial dosing of the first cohort in its Phase 1a dose-escalation clinical trial for TTX-MC138, an antisense oligonucleotide designed to inhibit microRNA-10b, a driver of metastasis in multiple cancers. Key points:
All patients in the cohort received their first dose an...
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
TransCode Therapeutics (NASDAQ: RNAZ) has completed initial dosing of the first cohort in its Phase 1a dose-escalation clinical trial for TTX-MC138, an antisense oligonucleotide designed to inhibit microRNA-10b, a driver of metastasis in multiple cancers. Key points:
All patients in the cohort received their first dose an...
$Transcode Therapeutics (RNAZ.US)$ Reuters· 1 min ago
Transcode Therapeutics Inc - No Significant Safety or Dose Limiting Toxicities Reported
Transcode Therapeutics Inc - No Significant Safety or Dose Limiting Toxicities Reported
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Lnova : r/s when ?